Carl Murphy
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 and COVID-19 Research 1
- Genetics 6
- Genetic Associations and Epidemiology 6
- Journals
- The Lancet (5 papers)Nature (4 papers)The Lancet Neurology (1 paper)Human Genetics and Genomics Advances (1 paper)Institutional Repositories DataBase (IRDB) (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Carl Murphy
11 papers receiving 2.4k citations
Carl Murphy's Hit Papers
Peers
Comparison fields: 5 of 100
- Infectious Diseases 1.6k
- Genetics 507
- Applied Microbiology and Biotechnology 34
- Internal Medicine 33
- Neurology 108
Countries citing papers authored by Carl Murphy
This map shows the geographic impact of Carl Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Murphy more than expected).
Fields of papers citing papers by Carl Murphy
This network shows the impact of papers produced by Carl Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Murphy. The network helps show where Carl Murphy may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | 2021 | 213 | |
| 7 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 8 | 2021 | 79 | |
| 9 | 2022 | 71 | |
| 10 | 2023 | 60 | |
| 11 | 2024 | 8 | |
| 12 | 2021 | 0 |
About Carl Murphy
Carl Murphy is a scholar working on Infectious Diseases, Genetics, Cardiology and Cardiovascular Medicine, Surgery and Nuclear Energy and Engineering, having authored 12 papers that have together received 2.5k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Genetic Associations and Epidemiology (6 papers), Knee injuries and reconstruction techniques (1 paper), Atrial Fibrillation Management and Outcomes (1 paper) and SARS-CoV-2 and COVID-19 Research (1 paper). The work is most often cited by research in Infectious Diseases (1.6k citations), Genetics (507 citations), Applied Microbiology and Biotechnology (34 citations), Internal Medicine (33 citations) and Neurology (108 citations). Carl Murphy has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, Nature, The Lancet Neurology, Human Genetics and Genomics Advances and Institutional Repositories DataBase (IRDB).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.